RECURSION PHARMACEUTICALS, INC. Deferred Tax Assets, Operating Loss Carryforwards
RECURSION PHARMACEUTICALS, INC. (RXRX) had Deferred Tax Assets, Operating Loss Carryforwards of $445.44 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-25
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $445.44M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $274.42M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $117.88M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $89.95M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $445.44M 10-K · filed 2026-02-25 |
| 2024-12-31 | $274.42M 10-K · filed 2026-02-25 |
| 2023-12-31 | $117.88M 10-K · filed 2025-02-28 |
| 2022-12-31 | $89.95M 10-K · filed 2024-02-29 |
| 2021-12-31 | $76.95M 10-K · filed 2023-02-27 |
| 2020-12-31 | $43.95M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |